Evidence map›Paper›PMID 25854283›Full record

ArticleClinical journal of the American Society of Nephrology : CJASN2015

Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome.

Caterina Mele, Mathieu Lemaire, Paraskevas Iatropoulos, Rossella Piras, Elena Bresin, Serena Bettoni, David Bick, Daniel Helbling, Regan Veith, Elisabetta Valoti and 8 more

Abstract read
In one paragraph

Article in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. X-linked C1GALT1C1 mutation causes atypical hemolytic uremic syndrome.European journal of human genetics : EJHG · 2023
    Article
  6. Kidney diseases.Immunological reviews · 2023
    Review
  7. Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022
    Article
  8. Frontiers in immunology · 2022
    Article
  9. A practical approach to the genomics of kidney disorders.Pediatric nephrology (Berlin, Germany) · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Molecular Studies and anFrontiers in medicine · 2020
    Article
  14. Article
  15. Article
  16. Article
  17. Pathogenesis of Atypical Hemolytic Uremic Syndrome.Journal of atherosclerosis and thrombosis · 2019
    Review
  18. Review
  19. Article
  20. Thrombotic Microangiopathy and the Kidney.Clinical journal of the American Society of Nephrology : CJASN · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Caterina MeleDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Mathieu LemaireDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Paraskevas IatropoulosDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Rossella PirasDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Elena BresinDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Serena BettoniDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
David BickDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Daniel HelblingDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Regan VeithDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Elisabetta ValotiDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Roberta DonadelliDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Luisa MurerDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Maria NeunhäusererDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Matteo BrenoDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Véronique Frémeaux-BacchiDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Richard LiftonDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Giuseppe RemuzziDue to the number of contributing authors,the affiliations are provided in the Supplemental Material. giuseppe.remuzzi@marionegri.it.
Marina NorisDue to the number of contributing authors,the affiliations are provided in the Supplemental Material.
Mario Negri Institute for Pharmacological Research · IT

Funding

Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI ARONSON, PETER S. · 2008 to 2022
$16.8M
Yale Center for Mendelian GenomicsUM1HG006504 · NHGRI · YALE UNIVERSITY · PI GERSTEIN, MARK BENDER, GUNEL, MURAT · 2016 to 2020
$14.8M
NHGRI NIH HHS UM1 HG006504NIDDK NIH HHS P30 DK079310
6 · The paper itself

Abstract

BACKGROUND AND

objectivesGenetic and acquired abnormalities causing dysregulation of the complement alternative pathway contribute to atypical hemolytic uremic syndrome (aHUS), a rare disorder characterized by thrombocytopenia, nonimmune microangiopathic hemolytic anemia, and acute kidney failure. However, in a substantial proportion of patients the disease-associated alterations are still unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Whole-exome and whole-genome sequencing were performed in two unrelated families with infantile recessive aHUS. Sequencing of cDNA from affected individuals was used to test for the presence of aberrant mRNA species. Expression of mutant diacylglycerol kinase epsilon (DGKE) protein was evaluated with western blotting.

resultsWhole-exome sequencing analysis with conventional variant filtering parameters did not reveal any obvious candidate mutation in the first family. The report of aHUS-associated mutations in DGKE, encoding DGKE, led to re-examination of the noncoding DGKE variants obtained from next-generation sequencing, allowing identification of a novel intronic DGKE mutation (c.888+40A>G) that segregated with disease. Sequencing of cDNA from affected individuals revealed aberrant forms of DGKE mRNA predicted to cause profound abnormalities in the protein catalytic site. By whole-genome sequencing, the same mutation was found in compound heterozygosity with a second nonsense DGKE mutation in all affected siblings of another unrelated family. Homozygous and compound heterozygous patients presented similar clinical features, including aHUS presentation in the first year of life, multiple relapsing episodes, and proteinuria, which are prototypical of DGKE-associated aHUS.

conclusionsThis is the first report of a mutation located beyond the exon-intron boundaries in aHUS. Intronic mutations such as these are underreported because conventional filtering parameters used to process next-generation sequencing data routinely exclude these regions from downstream analyses in both research and clinical settings. The results suggest that analysis of noncoding regions of aHUS-associated genes coupled with mRNA sequencing might provide a tool to explain genetically unsolved aHUS cases.

Indexed as

IntronsMutationAdolescentAtypical Hemolytic Uremic SyndromeBase SequenceBlotting, WesternChildDiacylglycerol KinaseDNA Mutational AnalysisFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHeterozygoteHomozygoteHumansInfantDGKE protein, humanDiacylglycerol Kinasecomplementdiacylglycerol kinase epsilongeneticshemolytic uremic syndromeintronic mutation

Identifiers

PMID25854283
PMCPMC4455211
OpenAlexW2314169644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.